Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT03955146 is registered in ClinicalTrials.gov with Kyntra Bio as lead sponsor.

NCT NCT03955146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03955146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Lead sponsor
Kyntra Bio
Phase
Phase 3
Overall status
Terminated
Start date
June 18, 2019
Completion date
August 28, 2023
Enrollment
393 (actual)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis